Myeloproliferative Neoplasms
Springer Berlin (Verlag)
978-3-642-24988-4 (ISBN)
Myeloproliferative neoplasms (MPNs) are clonal stem cell diseases that, under the World Health Organization classification, are subcategorized into eight clinicopathologic entities. The current book focuses on three of these categories: polycythemia vera, essential thrombocythemia, and primary myelofibrosis. A number of important questions regarding the diagnosis, prognosis, and treatment of these diseases have arisen following the discovery of the JAK2 V617F mutation in the majority of patients with bcr/abl-negative MPNs.
This book comprises evidence-based reviews and expert consensus results. It offers comprehensive coverage of relevant laboratory and clinical advances and places great emphasis on the practical issues that challenge physicians in their daily practice. The main topics considered thus include contemporary diagnostic approaches, the value and limitations of mutation screening for diagnostic and prognostic purposes, risk stratification in terms of both survival and other disease complications such as leukemic transformation and thrombosis, and modern therapeutic strategies, including conventional drugs, allogeneic stem cell transplantation, and experimental drugs still under study. The reader will find Critical Concepts and Management Recommendations in Myeloproliferative Neoplasms to be an invaluable and up-to-date source of information from leading authorities in the field.
The discovery of the JAK2 V617F mutation in the majority of patients with bcr/abl-negative myeloproliferative neoplasms has stimulated a number of questions regarding the diagnosis, prognosis, and treatment of polycythemia vera, essential thrombocythemia, and primary myelofibrosis. This book provides evidence-based reviews and expert consensus results concerning the key clinical issues for patient management. Practical recommendations are provided for the optimization and standardization of management of all three types of myeloproliferative neoplasm. Risk stratification, treatment goals, and first- and second-line therapies are discussed in detail, and other relevant diagnostic and research issues are also addressed. The reader will find Critical Concepts and Management Recommendations in Myeloproliferative Neoplasms to be an invaluable and up-to-date source of information from leading authorities in the field.
Biology.- Gerneral Issues in the Management of MPNs.- Specific Issues of Treatment in PV and ET.- Treatment of PMF.- Research Issues and Perspectives.
| Erscheint lt. Verlag | 3.2.2012 |
|---|---|
| Reihe/Serie | Hematologic Malignancies |
| Zusatzinfo | VIII, 240 p. |
| Verlagsort | Berlin |
| Sprache | englisch |
| Maße | 178 x 254 mm |
| Gewicht | 694 g |
| Themenwelt | Medizinische Fachgebiete ► Innere Medizin ► Hämatologie |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie | |
| Schlagworte | Myeloproliferative • Myeloproliferatives Syndrom • Neoplasms • polycythemia vera • Primary Myelofibrosis • Thrombocythemia |
| ISBN-10 | 3-642-24988-4 / 3642249884 |
| ISBN-13 | 978-3-642-24988-4 / 9783642249884 |
| Zustand | Neuware |
| Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
